William Blair downgraded Nkarta (NKTX) to Market Perform from Outperform without a price target The firm views the company’s expansion into primary membranous nephropathy positively. However, the protocol modifications to include flu in the preconditioning regimen “gives us pause” as it is unclear if the decision was partly influenced by some early clinical data from the trials, the analyst tells investors in a research note. Blair says that without a reduced lymphodepletion regimen, it finds it increasingly challenging to discern how NKX019 may be differentiated from other Covid-19 allogeneic cell therapies in the increasingly competitive autoimmune disease space.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NKTX:
- Nkarta reports Q1 EPS (43c), consensus (45c)
- Nkarta’s Strategic Workforce Reduction and Clinical Progress Justify Buy Rating
- Nkarta price target lowered to $14 from $15 at Stifel
- Nkarta’s Strategic Restructuring and NKX019 Progress Drive Buy Rating
- Nkarta Announces Major Restructuring and Leadership Changes